Estrella Immunopharma Inc
NASDAQ:ESLA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Estrella Immunopharma Inc
Cash from Operating Activities
Estrella Immunopharma Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
Estrella Immunopharma Inc
NASDAQ:ESLA
|
Cash from Operating Activities
-$1.8m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Baker Hughes Co
NASDAQ:BKR
|
Cash from Operating Activities
$3.8B
|
CAGR 3-Years
26%
|
CAGR 5-Years
24%
|
CAGR 10-Years
8%
|
|
|
Schlumberger NV
NYSE:SLB
|
Cash from Operating Activities
$6.5B
|
CAGR 3-Years
20%
|
CAGR 5-Years
17%
|
CAGR 10-Years
-3%
|
|
|
Halliburton Co
NYSE:HAL
|
Cash from Operating Activities
$2.8B
|
CAGR 3-Years
5%
|
CAGR 5-Years
9%
|
CAGR 10-Years
4%
|
|
|
Symbotic Inc
NASDAQ:SYM
|
Cash from Operating Activities
$866.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
R
|
Reddit Inc
NYSE:RDDT
|
Cash from Operating Activities
$690.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Estrella Immunopharma Inc
Glance View
Estrella Immunopharma Inc is a US-based company operating in industry. The company is headquartered in Emeryville, California. The company went IPO on 2021-07-19. Estrella Immunopharma, Inc. is a preclinical-stage biopharmaceutical company. The firm is developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The firm is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The firm is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors.
See Also
What is Estrella Immunopharma Inc's Cash from Operating Activities?
Cash from Operating Activities
-1.8m
USD
Based on the financial report for Dec 31, 2025, Estrella Immunopharma Inc's Cash from Operating Activities amounts to -1.8m USD.
What is Estrella Immunopharma Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
-20%
Over the last year, the Cash from Operating Activities growth was 43%. The average annual Cash from Operating Activities growth rates for Estrella Immunopharma Inc have been -20% over the past three years .
